Black Diamond Therapeutics, Inc. (BDTX)

NASDAQ: BDTX · IEX Real-Time Price · USD

5.30

-0.40 (-7.02%)

At close: Apr 18, 2024, 4:00 PM

5.14

-0.16 (-3.02%)

Pre-market: Apr 19, 2024, 5:05 AM EDT

BDTX Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Cash & Equivalents	57.04	35.48	67.02	35.83	154.72	51.66	7.88
Short-Term Investments	75.18	88.49	143.99	280.46	0	0	0
Cash & Cash Equivalents	132.22	123.98	211.01	316.29	154.72	51.66	7.88
Cash Growth	6.65%	-41.25%	-33.29%	104.43%	199.50%	555.75%	-
Other Current Assets	1.81	3.73	4.69	3.26	0.99	0.02	0.04
Total Current Assets	134.03	127.71	215.7	319.55	155.71	51.68	7.91
Property, Plant & Equipment	23.71	27.38	30.74	8.79	0.16	0.13	0.1
Other Long-Term Assets	0.82	1.17	1.24	1.33	2.42	0.01	0.01
Total Long-Term Assets	24.53	28.55	31.98	10.12	2.58	0.14	0.11
Total Assets	158.57	156.26	247.68	329.67	158.3	51.83	8.02
Accounts Payable	2.32	1.88	4.11	2.54	1.96	2.12	2.07
Other Current Liabilities	17.32	13.38	19.54	11.68	2.9	0.45	0.16
Total Current Liabilities	19.65	15.26	23.64	14.22	4.86	2.58	2.23
Long-Term Debt	22.19	25.3	28.14	7.69	0	0	0
Other Long-Term Liabilities	0	0	0	0	0.02	4.02	0.01
Total Long-Term Liabilities	22.19	25.3	28.14	7.69	0.02	4.02	0.01
Total Liabilities	41.83	40.56	51.78	21.91	4.88	6.6	2.24
Total Debt	22.19	25.3	28.14	7.69	0	0	0
Debt Growth	-12.31%	-10.10%	265.74%	-	-	-	-
Retained Earnings	-417.43	-334.99	-243.82	-118.22	-50.97	-15.71	-6.78
Comprehensive Income	-0.03	-1.82	-0.41	0.61	0	0	0
Shareholders' Equity	116.74	115.7	195.9	307.76	-47.16	-15.54	-6.68
Net Cash / Debt	110.04	98.68	182.87	308.6	154.72	51.66	7.88
Net Cash / Debt Growth	11.51%	-46.04%	-40.74%	99.45%	199.50%	555.75%	-
Net Cash Per Share	2.50	2.72	5.05	9.38	74.54	25.59	4.09
Working Capital	114.39	112.45	192.06	305.34	150.85	49.11	5.68
Book Value Per Share	2.66	3.19	5.41	9.35	-22.72	-7.70	-3.47

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).